Neurooncology Tuebingen
LightNews LightNews
banner
neurooncotue.bsky.social
Neurooncology Tuebingen
@neurooncotue.bsky.social
100 followers 120 following 15 posts
Interdiciplinary neurooncologcial activities and research at the Tuebinger university hospital
🧠 @hih-tuebingen.bsky.social
🎓 @unituebingen.bsky.social
🧠 Website: https://www.hih-tuebingen.de/forschung/neuroonkologie
Posts Replies Media Videos
neurooncotue.bsky.social
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions!
Looking forward to Rome!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
October 21, 2025 at 8:22 AM
neurooncotue.bsky.social
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
October 18, 2025 at 10:48 AM
neurooncotue.bsky.social
Great talk by @ghtabatabai.bsky.social about time management in academia
@eanoassociation.bsky.social
October 18, 2025 at 8:03 AM
neurooncotue.bsky.social
Great poster session with nice discussions about our current work!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
October 17, 2025 at 6:03 PM
neurooncotue.bsky.social
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social
@hannes-becker1996.bsky.social
@ghtabatabai.bsky.social
ghtabatabai.bsky.social Ghazaleh Tabatabai @ghtabatabai.bsky.social · 25d
And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
October 17, 2025 at 5:01 PM
neurooncotue.bsky.social
@eanoassociation.bsky.social
ghtabatabai.bsky.social Ghazaleh Tabatabai @ghtabatabai.bsky.social · 25d
Just happening. Max Niyazi on stage at EANO 2025 👍🏼💡
October 17, 2025 at 2:40 PM
Reposted by Neurooncology Tuebingen
ghtabatabai.bsky.social
Just happening. Max Niyazi on stage at EANO 2025 👍🏼💡
October 17, 2025 at 2:36 PM
neurooncotue.bsky.social
Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen.
More to come!
@eanoassociation.bsky.social
October 17, 2025 at 7:38 AM
Reposted by Neurooncology Tuebingen
eanoassociation.bsky.social
🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities.
🔗 academic.oup.com/neuro-oncolo...

#NeuroOncology
August 23, 2025 at 8:17 AM
Reposted by Neurooncology Tuebingen
eanoassociation.bsky.social
🚨 At #EANO2025, we already expect more than 1,200 participants! Don’t miss out on this fantastic experience to meet experts in the field of #NeuroOncology from all over the world. Registration is still open eano.eu/eano2025/ We can’t wait to see you in #Prague!
September 26, 2025 at 9:37 AM
Reposted by Neurooncology Tuebingen
eanoassociation.bsky.social
🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice.
🔗 academic.oup.com/neuro-oncolo...
September 24, 2025 at 12:28 PM
neurooncotue.bsky.social
Innovative trial design, thank you for the opportunity for being part of it!
September 29, 2025 at 7:30 AM
neurooncotue.bsky.social
Extremely happy that we could have contributed!
michael-platten.bsky.social Michael Platten, MD @michael-platten.bsky.social · Jul 29
Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/
September 29, 2025 at 7:26 AM
neurooncotue.bsky.social
Thank you for having the opportunity to present our data at this year DGNC in Hanover.
#DGNC2025
June 3, 2025 at 7:38 AM
Reposted by Neurooncology Tuebingen
ghtabatabai.bsky.social
Almost 25 year old T-shirt, reminds me of great experience at MGH/HMS 2000/2001, @harvard.edu - hard to see this institution under pressure now, and impressed by the integrity and resilience of Harvard leadership (more on LinkedIn) 🙌 #Harvard #AcademicFreedom #ScienceForDemocracy #ScienceMatters
April 20, 2025 at 7:19 PM
neurooncotue.bsky.social
Happy to represent Tuebingen in this initiative!
#aufstehenfuerdemokratie
February 20, 2025 at 10:40 PM
Reposted by Neurooncology Tuebingen
ghtabatabai.bsky.social
Tübingen 12 Feb 2025
Geschwister Scholl Platz
Democracy needs facts
Science needs Democracy.
#aufstehenfuerdemokratie
February 12, 2025 at 6:58 PM
neurooncotue.bsky.social
We are more than happy that our publication "The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy" is accepted by Neurooncology Advances.

academic.oup.com/noa/advance-...

Check it out ;)

@unituebingen.bsky.social
@hih-tuebingen.bsky.social
The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy
AbstractBackground. Ependymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical re
academic.oup.com
January 16, 2025 at 2:42 PM
Reposted by Neurooncology Tuebingen
unituebingen.bsky.social
👍 Herzlich Willkommen auf dem Bluesky-Account der #unituebingen. Wir posten ab sofort hier und auf unseren anderen Kanälen, z.B. Instagram, Facebook, LinkedIn, Mastodon. Unsere Aktivitäten auf X haben wir beendet.
January 13, 2025 at 9:21 AM
neurooncotue.bsky.social
Happy to see this finally out after a long team effort! 🎉🎉🎉
@hih-tuebingen.bsky.social
@ghtabatabai.bsky.social
January 7, 2025 at 9:08 PM
Reposted by Neurooncology Tuebingen
ghtabatabai.bsky.social
Merry Christmas and very best wishes für 2025!
@hih-tuebingen.bsky.social @unituebingen.bsky.social @neurooncotue.bsky.social
December 25, 2024 at 11:13 AM
Reposted by Neurooncology Tuebingen
icomeningioma.bsky.social
New insights into #meningiomas, with The Brain Tumour Charity’s funding and led by @gelarehzadeh.bsky.social, has been included in their #Research Highlights of 2024.

Read more about it here: www.thebraintumourcharity.org/news/researc...
Research highlights of 2024
December 18, 2024 at 1:30 PM
Reposted by Neurooncology Tuebingen
mathiasjucker.bsky.social
Two flagship chair professorships for neurodgenerative diseases in Tübingen, Germany. Both affiliated with our university @hih-tuebingen.bsky.social and the German Center for Neurodegenerative diseases @dzne.science. Apply and join us!
www.nature.com/naturecareer...
www.nature.com/naturecareer...
Nature Careers | Science jobs | Choose from 1,225 live vacancies
Search for your next job from 1,225 live vacancies, or upload your CV now and let recruiters find you
nature.com
December 16, 2024 at 4:14 PM
Reposted by Neurooncology Tuebingen
hih-tuebingen.bsky.social
📢The Faculty of Medicine at the University of Tübingen invites applications for a position at the Hertie Center for Neurology for an Endowed #Professorship (W3) in #Neurology with a Focus on #Neurodegenerative #Diseases, available by 1 October 2026, potentially earlier
Full PDF: tinyurl.com/y6bfky83
December 17, 2024 at 8:24 AM
Reposted by Neurooncology Tuebingen
icomeningioma.bsky.social
@ghtabatabai is a neurologist and a physician scientist at the University of Tübingen and the Managing Director Neurology at the University Hospital Tübingen.

Her research includes target discovery & validation, molecular mechanisms of treatment resistance, & novel delivery routes to brain tumors.
Member Spotlight: Dr. Ghazaleh Tabatabai
December 16, 2024 at 11:46 AM